



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

AZ194

Cat. No.:	HY-145169
CAS No.:	2241651-99-8
Molecular Formula:	C ₃₄ H ₃₁ F ₂ N ₃ O ₃
Molecular Weight:	567.63
Target:	Sodium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (58.72 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	1.7617 mL	8.8086 mL	17.6171 mL
		5 mM	0.3523 mL	1.7617 mL	3.5234 mL
		10 mM	0.1762 mL	0.8809 mL	1.7617 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of Nav1.7 (IC ₅₀ =1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed Nav1.7. Antinociceptive effects ^[1] .
In Vivo	AZ194 would provide pain relief in rat models of chemotherapy- and nerve injury- induced neuropathic pain. AZ194 (orally; at 2 and 10 mg/kg) restores mechanical sensitivity in animals with chemotherapy-induced and nerve injury-induced neuropathic nociception ^[1] . AZ194 (10 mg/kg; ip; CD1 male mice) does not affect motor performance (open field). AZ194 synergizes with commonly used painkillers, engages Nav1.7-dependent endogenous opioid signaling ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cai S, et al. Selective targeting of Nav1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Sci Transl Med. 2021;13(619):eabh1314.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA